
 
													
 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pozelimab,Cemdisiran,Ravulizumab
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Poze-Cemdi Combo Controls Intravascular Hemolysis in PNH Patients Vs Ravulizumab
Details : Veopoz (pozelimab) is a complement C5 inhibitor antibody, which is being evaluated in combination with cemdisiran for the treatment of paroxysmal nocturnal hemoglobinuria.
Product Name : Veopoz
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 07, 2024
Lead Product(s) : Pozelimab,Cemdisiran,Ravulizumab
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cemdisiran
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cemdisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemoglobinuria, Paroxysmal.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
November 23, 2021
Lead Product(s) : Cemdisiran
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Cemdisiran
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Alnylam Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Eculizumab to Cemdisiran Switch in aHUS
Details : Cemdisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Atypical Hemolytic Uremic Syndrome.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
June 27, 2019
Lead Product(s) : Cemdisiran
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Alnylam Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cemdisiran
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
Details : Cemdisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glomerulonephritis, IGA.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
February 15, 2019
Lead Product(s) : Cemdisiran
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cemdisiran
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cemdisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Atypical Hemolytic Uremic Syndrome.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
October 06, 2017
Lead Product(s) : Cemdisiran
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cemdisiran
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
Details : ALN-PCSSC is a Oligonucleotide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Homozygous Familial Hypercholesterolemia.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
November 15, 2016
Lead Product(s) : Cemdisiran
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cemdisiran
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)
Details : ALN-PCSSC is a Oligonucleotide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Atherosclerosis.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
November 05, 2015
Lead Product(s) : Cemdisiran
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cemdisiran
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : The Medicines Company
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALN-PCSSC is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypercholesterolemia.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
December 11, 2014
Lead Product(s) : Cemdisiran
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : The Medicines Company
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All